US Stock Market Move | General Motors Company (GM.US) rose nearly 6% after announcing that its expected earnings for 2026 are higher than anticipated. The company also announced a $6 billion increase in its share buyback program.
On Tuesday, General Motors (GM.US) rose by nearly 6%, closing at $84.15.
On Tuesday, General Motors Company (GM.US) rose nearly 6% to $84.15. The financial report showed that General Motors Company's revenue in Q4 2025 decreased by 5.1% year-on-year to $45.29 billion, below the analysts' consensus of $45.8 billion; the net loss attributable to shareholders was $3.31 billion, higher than the net loss of $2.96 billion in the same period last year. The adjusted earnings before interest and taxes (EBIT) margin was 6.3%, higher than the 5.3% in the same period last year. The adjusted earnings per share were $2.51, a 30.4% increase year-on-year, better than the analysts' consensus of $2.20.
Looking ahead, General Motors Company expects that in 2026, the adjusted EBIT will be $13-15 billion, with the midpoint better than the analysts' consensus of $13.39 billion; the net profit is expected to be $10.3-11.7 billion; and the adjusted earnings per share is expected to be $11.00-13.00, with the midpoint better than the analysts' consensus of $11.73. Additionally, the Board of Directors of General Motors Company announced an increase in quarterly dividends by $0.03 to $0.18 per share, and approved a new $6 billion stock buyback program.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


